Prospect: Patient Information
Pregabalina SUN 150 mg Hard Capsules EFG
Read this prospect carefully before starting to take this medication, as it contains important information for you.
Pregabalina SUN belongs to a group of medications used for the treatment of epilepsy, neuropathic pain, and generalized anxiety disorder (GAD) in adults.
Peripheral and central neuropathic pain:Pregabalina SUN is used for the treatment of chronic pain caused by nerve damage. Various diseases can cause peripheral neuropathic pain, such as diabetes or herpes. The pain sensation could be described as heat, burning, pulsating pain, stabbing pain, acute pain, spasms, continuous pain, numbness, tingling, and a sensation of pins and needles. Peripheral and central neuropathic pain could also be associated with mood changes, sleep disturbances, fatigue (tiredness), and can affect physical and social activity and overall quality of life.
Epilepsy:Pregabalina SUN is used in the treatment of certain types of epilepsy (partial seizures with or without secondary generalization) in adults. Your doctor will prescribe pregabalina to treat epilepsy when your current treatment does not control the disease. You must take Pregabalina SUN in addition to your current treatment. Pregabalina SUN should not be administered alone, but always used in combination with other antiepileptic treatments.
Generalized anxiety disorder:Pregabalina SUN is used in the treatment of generalized anxiety disorder (GAD). Symptoms of GAD include excessive and prolonged anxiety and worry that are difficult to control. GAD can also produce restlessness or a feeling of excitement or nervousness, feeling easily fatigued (tired), having difficulty concentrating or feeling mentally blank, irritability, muscle tension, or sleep disturbances. This is different from the stress and tensions of everyday life.
Do not take Pregabalina SUN
If you are allergic to pregabalin or any of the other ingredients of this medication (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting to take Pregabalina SUN
Some people may become dependent on pregabalin (need to continue taking this medication). They may experience withdrawal effects when they stop taking pregabalin (see section 3 “How to take Pregabalina SUN” and “If you interrupt treatment with Pregabalina SUN”.
If you are concerned that you may become dependent on pregabalin, it is essential that you consult with your doctor.
If you notice any of the following symptoms while taking Pregabalina SUN, it could be a sign that you have become dependent:
If you notice any of these symptoms, talk to your doctor to analyze the best treatment for you, even to see when it is appropriate to stop taking this medication and how to do it safely.
Children and adolescents
The safety and efficacy of pregabalin have not been established in children and adolescents (under 18 years) so pregabalin should not be used in this age group.
Taking Pregabalina SUN with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Pregabalin and certain medications may influence each other (interactions). When pregabalin is used with certain medications that have a sedative effect (including opioids), these effects may be potentiated, and may lead to respiratory failure, coma, and death. The degree of dizziness, somnolence, and decreased concentration may increase if pregabalin is taken with other medications that contain:
Oxycodone – (used as an analgesic)
Lorazepam – (used to treat anxiety)
Alcohol
Pregabalina SUN can be taken with oral contraceptives.
Taking Pregabalina SUN with food, drinks, and alcohol
Pregabalina SUN capsules can be taken with or without food
It is recommended not to take alcohol during pregabalin treatment.
Pregnancy, breastfeeding, and fertility
You should not take pregabalin during pregnancy or breastfeeding, unless your doctor has told you to.
The use of pregabalin during the first 3 months of pregnancy may cause congenital anomalies in the fetus that require medical treatment. In a study that reviewed data from women in Nordic countries who took pregabalin during the first 3 months of pregnancy, 6 out of 100 babies had such congenital anomalies. This contrasts with 4 out of 100 babies born to women not treated with pregabalin in the study. Congenital anomalies of the face (cleft palate), eyes, nervous system (including the brain), kidneys, and genitals have been reported.
A reliable contraceptive method should be used in women of childbearing age. If you are pregnant or breastfeeding, believe you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
Pregabalin may cause dizziness, somnolence, and decreased concentration. You should not drive, operate heavy machinery, or engage in other potentially hazardous activities until you know if this medication affects your ability to perform these activities.
Pregabalina SUN contains sodium and mannitol
This medication contains less than 1 mmol of sodium (23 mg) per hard capsule; it is essentially “sodium-free”.
Mannitol may have a mild laxative effect.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again. Do not take more doses than prescribed.
Your doctor will determine the appropriate dose for you.
Pregabalina is exclusively for oral use.
Peripheral and central neuropathic pain, epilepsy, or generalized anxiety disorder:
If you estimate that the action of this medication is too strong or too weak, inform your doctor or pharmacist.
If you are an elderly patient (over 65 years old), you should take pregabalina normally, except if you have kidney problems.
Your doctor may prescribe a different dosing regimen and/or different doses if you have kidney problems.
Swallow the capsule whole with water.
Continue taking pregabalina until your doctor tells you to stop.
If you take more Pregabalina SUN than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
As a result of taking more pregabalina than you should, you may feel drowsy, confused, agitated, or restless. Seizures and loss of consciousness (coma) have also been reported.
If you forgot to take Pregabalina SUN
It is essential to take the pregabalina capsules regularly at the same hour every day. If you forget to take a dose, take it as soon as you remember, unless it is time for the next dose. In that case, continue with the next dose normally. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Pregabalina SUN
Do not stop taking pregabalina abruptly. If you want to stop taking pregabalina, discuss it with your doctor first. He will instruct you on how to do it. If you interrupt the treatment, you should do it gradually for a minimum of one week.
Once the treatment with pregabalina is completed, whether short-term or long-term, you should know that you may experience certain adverse effects, known as withdrawal symptoms. These effects include insomnia, headaches, nausea, anxiety, diarrhea, flu-like symptoms, seizures, nervousness, depression, thoughts of self-harm or suicide, pain, sweating, and dizziness. These symptoms may appear more frequently or severely if you have been taking this medication for a longer period. If you experience withdrawal symptoms, contact your doctor.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects:
If you experience any of the following severe side effects, discontinue treatment with Pregabalina SUN and contact your doctor or visit the nearest hospital, as you may need urgent medical attention.
If you experience facial swelling or tongue swelling, or if your skin becomes red and presents blisters or peeling, you must seek immediate medical assistance.
Other side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare: may affect up to 1 in 10,000 people
Not known: their frequency cannot be estimated from available data
After discontinuing short-term or long-term treatment with Pregabalina Sun, you should know that you may experience certain side effects, known as withdrawal symptoms (see “If you discontinue treatment with Pregabalina SUN”).
Certain side effects, such as dizziness, may be more frequent as patients with spinal cord injury may be taking other medications to treat, for example, pain or spasticity (tense or rigid muscles), with side effects similar to those of Pregabalin, so the intensity of these side effects may increase when taken together.
The following adverse reaction has been reported in post-marketing experience: difficulty breathing, shallow breathing.
Reporting of adverse reactions
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse reactions, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Container: Once opened, capsules must be used within the next 30 days.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and unused medications at the SIGRE drop-off point at the pharmacy.Ask your pharmacist how to dispose of packaging and unused medications if you are unsure. By doing so, you will help protect the environment.
Pregabalina SUN Composition
The active ingredient is pregabalina. Each hard capsule contains 150 mg of pregabalina.
The other components are:
Capsule content:
Manitol, talco
Capsule composition:
Gelatina, dióxido de titanio (E171), agua purificada, laurilsulfato sódico
Printing ink:
Laca Shellac, propilenglicol, óxido de hierro negro (E172), hidróxido de potasio
Appearance of the product and packaging contents
Pregabalina SUN 150 mg hard capsules:
Hard gelatin capsules of size “2” with opaque white cap and opaque white body marked with “rbx” in black ink on the cap and with “PG150” on the body containing white or off-white powder. The length of the capsule is approximately 17.0 – 18.2 mm.
OPA/Al/PVC/Al blister:
Packaging sizes: 14, 21, 56, 84, 98, 100 or 112 hard capsules
PVC/Aluminium blister:
Packaging sizes: 14, 21, 28, 56, 84, 98, 100 or 112 hard capsules.
HDPE bottle with child-resistant closure:
Packaging sizes: 14, 21, 30, 56, 84, 98, 100 or 112 hard capsules.
HDPE bottle with screw cap:
Packaging size: 500 hard capsules
Only some packaging sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Sun Pharmaceutical Industries Europe B.V.,
Polarisavenue 87,
2132JH Hoofddorp, Netherlands
Responsible manufacturer:
Terapia, S.A.
124, Fabricii Street
400 632 – Cluj Napoca
Romania
or
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132JH Hoofddorp
Netherlands
Local representative
Sun Pharma Laboratorios, S.L.
Rambla de Catalunya 53-55
08007 - Barcelona
Spain
+34 93 342 78 90
This medicinal product is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
France:PREGABALINE CRISTERS PHARMA 150 mg, gélule
Germany:PREGABALIN BASICS 150 mg Hartkapseln
Netherlands:Pregabaline SUN 150 mg, harde capsules
Poland:Tabagine
Romania:Pregabalina Terapia 150 mg capsule
United Kingdom (Northern Ireland):Pregabalin Sun 150 mg Capsules, Hard
Last review date of this leaflet:January 2024
The detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.